Picard Medical / SynCardia to Participate in Inaugural “Hands-On Training Day” at the Technology and Heart Failure Therapeutics Conference

Rhea-AI Summary

Picard Medical (NYSE American: PMI) and SynCardia will lead hands-on clinical training at the inaugural Hands-On Training Day at Technology and Heart Failure Therapeutics (THT) 2026 in Boston on March 1, 2026. The session features case-based instruction on the SynCardia Total Artificial Heart and portable drivers to strengthen multidisciplinary care.

News Market Reaction – PMI

-0.86%

1 alert

-0.86% Session close to close

+3.3% Peak Tracked

$85.49M Market Cap

3.55K Volume

In the Feb 26 session, PMI declined 0.86%, reflecting a mild negative market reaction. Argus tracked a peak move of +3.3% during that session.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Picard Medical’s emphasis on clinician training and real‑world use of t...

Analysis

This announcement highlights Picard Medical’s emphasis on clinician training and real‑world use of the SynCardia Total Artificial Heart, adding to recent educational events and conference participation. Against this operational backdrop, SEC filings detail a proposed increase to 300,000,000 authorized common shares, registration of 17,000,000 shares for resale, and senior secured notes totaling up to $50,000,000. With an accumulated deficit of $72.6 million, investors may monitor execution on adoption efforts alongside balance sheet and dilution dynamics.

Key Figures

Authorized common stock: 300,000,000 shares Shares outstanding: 73,701,176 shares Registered resale shares: 17,000,000 shares +5 more

8 metrics

Authorized common stock 300,000,000 shares Proposed increase in DEFR14A/DEF 14A proxy for March 10, 2026 meeting

Shares outstanding 73,701,176 shares Common stock outstanding as of February 6, 2026

Registered resale shares 17,000,000 shares Shares registered for resale via S-1/S-1A and 424B3

Warrant shares 7,009,346 shares Common shares issuable upon warrant exercise at $2.675

Conversion shares 9,990,654 shares Common shares issuable upon note conversion or settlement

Initial note principal $15,000,000 Senior secured notes issued under financing facility

Additional note capacity $35,000,000 Further senior secured notes permitted under facility

Accumulated deficit $72.6 million As of September 30, 2025 per S-1/A

Historical Context

5 past events · Latest: Feb 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 23	Surgical training event	Positive	-7.1%	Houston training village for SynCardia Total Artificial Heart surgical education.
Feb 12	Clinical milestone case	Positive	-1.2%	Successful bridge‑to‑transplant case at UCSF using SynCardia Total Artificial Heart.
Feb 10	Conference presentation	Positive	-4.2%	Planned data presentation on Emperor electromechanical Total Artificial Heart at EUMS.
Jan 29	Educational webinar	Positive	-2.8%	DeviceTalks webinar on Emperor fully implantable Total Artificial Heart preclinical data.
Jan 13	Podcast launch	Positive	+4.8%	Cruxx of MedTech podcast series on SynCardia Total Artificial Heart and Emperor device.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent clinically focused and outreach-heavy news has generally been positive in tone but often met with negative price reactions, suggesting a pattern of selling into good operational headlines.

Recent Company History

Over the past months, Picard Medical has focused on expanding awareness and clinical adoption of the SynCardia Total Artificial Heart. Events include a Houston surgical training program on Feb 24, 2026 (news on Feb 23), a successful bridge‑to‑transplant case at UCSF, and multiple scientific and educational presentations around the Emperor fully implantable TAH. Most of these news items were followed by short‑term price declines despite operationally positive messaging, making today’s educational conference participation consistent with this broader commercialization narrative.

Key Terms

mechanical circulatory support, hemodynamic monitoring, cardiogenic shock, total artificial heart, +1 more

5 terms

mechanical circulatory support medical

"advance education in temporary and durable mechanical circulatory support, hemodynamic"

Mechanical circulatory support are medical devices that help or take over the heart’s job of moving blood around the body, ranging from temporary external pumps to implanted pumps that assist one or both sides of the heart. For investors, these devices matter because their use drives sales, regulatory scrutiny, reimbursement decisions and long‑term healthcare costs; think of them as a backup engine for a failing heart whose adoption and outcomes influence a company’s market opportunity and risk profile.

hemodynamic monitoring medical

"durable mechanical circulatory support, hemodynamic monitoring, and the management of"

Hemodynamic monitoring is the continuous measurement of blood flow, blood pressure and how well the heart is pumping, using devices or sensors in patients who are critically ill or undergoing surgery. For investors, it signals demand and regulatory risk for medical devices and services that help doctors spot deterioration or guide treatment — like dashboard gauges in a car that tell you when the engine needs attention and influence buying and reimbursement decisions.

cardiogenic shock medical

"hemodynamic monitoring, and the management of cardiogenic shock."

Cardiogenic shock is a life-threatening condition in which the heart suddenly cannot pump enough blood to meet the body’s needs, causing organ failure and very low blood pressure. Investors watch it because its incidence, treatment options, and survival rates affect demand for medical devices, drugs, hospital resources and clinical-trial outcomes; a new therapy or safety concern tied to cardiogenic shock can materially change a healthcare company’s revenue and regulatory risk.

total artificial heart medical

"application of the SynCardia Total Artificial Heart in advanced heart failure patients"

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

biventricular heart failure medical

"patient care best practices in complex cases of advanced biventricular heart failure."

Biventricular heart failure is a condition where both the right and left sides of the heart are weakened and cannot pump blood effectively, like a two-pump system losing power on both ends. It matters to investors because it increases demand for treatments, medical devices, hospital care and long-term therapies, can drive clinical-trial activity and regulatory decisions, and may affect costs and revenue for companies in cardiovascular drugs, devices and healthcare services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Training will consist of an interactive clinical education program highlighting real world application of the SynCardia Total Artificial Heart in advanced heart failure patients –

TUCSON, Ariz., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will participate in the inaugural “Hands-On Training Day” at the Technology and Heart Failure Therapeutics (THT) 2026 conference to be held in Boston on March 1^st 2026.

This interactive, case-based program hosted for the first time at the conference will bring together leading clinicians and innovators to advance education in temporary and durable mechanical circulatory support, hemodynamic monitoring, and the management of cardiogenic shock. Through hands-on training and real-world clinical scenarios, the program is designed to strengthen multidisciplinary collaboration among practitioners and improve patient outcomes in advanced heart failure.

Stephen Zamojski, Head of Global Sales and Clinical Education at SynCardia Systems LLC, commented, “As adoption of total artificial heart therapy continues to expand, education and hands-on familiarity are critical. By engaging directly with the technology in a collaborative setting, clinicians can deepen their understanding of how the SynCardia Total Artificial Heart supports patients through the most advanced stages of heart failure. Our participation in the inaugural Hands-On Training Day at THT 2026 follows the successful SynCardia Training Village held in Houston earlier this week and reflects a key component of our commercial expansion strategy. We remain focused on building strong clinical partnerships, expanding global awareness, and ensuring that leading heart failure centers are equipped to deliver this life-saving therapy.”

Picard Medical / SynCardia is proud to support this important educational initiative and looks forward to engaging with physicians, fellows, and multidisciplinary clinical teams as it continues to expand global awareness and adoption of total artificial heart therapy. Senior Clinical Specialists, Lauren Wallace, and Skyler Peffly, will lead the training, offering participants direct, hands-on interaction with the Companion 2 Driver, the Freedom Portable Driver, and the SynCardia Total Artificial Heart.

Attendees will rotate through interactive stations in a small group setting designed to foster focused instruction, peer exchange, and active problem solving. The session will incorporate real-world clinical scenarios and guided discussion to support clinical decision-making, device management, and patient care best practices in complex cases of advanced biventricular heart failure.

About THT 2026
Technology and Heart Failure Therapeutics (THT) 2026 is an international conference focused on advancing innovation in heart failure through emerging device, technology, and combination therapies. Sponsored by the Cardiovascular Research Foundation, THT brings together leading clinicians, researchers, and industry partners to share the latest clinical data, discuss regulatory and commercial pathways, and explore future trends shaping the management of advanced heart failure. The multidisciplinary program features cutting- edge scientific sessions, case-based discussions, and hands-on training designed to foster collaboration and improve patient outcomes. For more information, visit https://www.thtmeeting.com/about-tht.

About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

What will Picard Medical (PMI) present at the THT 2026 Hands-On Training Day on March 1, 2026?

Picard Medical will deliver an interactive, case-based training focused on SynCardia device use and management. According to the company, sessions include hands-on interaction with the SynCardia Total Artificial Heart, Companion 2 Driver, and Freedom Portable Driver for multidisciplinary clinician teams.

Who will lead the SynCardia hands-on training for Picard Medical (PMI) at THT 2026 in Boston?

Senior Clinical Specialists Lauren Wallace and Skyler Peffly will lead the training sessions. According to the company, they will guide small-group rotations, device handling, clinical scenarios, and peer discussion to support decision-making in advanced biventricular heart failure.

How does the THT 2026 Hands-On Training Day support adoption of the SynCardia Total Artificial Heart (PMI)?

The program aims to expand clinical familiarity and collaboration to improve patient care with SynCardia therapy. According to the company, hands-on practice, real-world scenarios, and multidisciplinary interaction are intended to deepen clinician competence and drive broader adoption.

When and where is Picard Medical (PMI) hosting the Hands-On Training Day at THT 2026?

The Hands-On Training Day will take place in Boston on March 1, 2026 as part of THT 2026. According to the company, this inaugural, case-based program is hosted within the conference to reach clinicians and heart failure centers.

What devices will participants use during the SynCardia training session by Picard Medical (PMI)?

Participants will handle the SynCardia Total Artificial Heart, Companion 2 Driver, and Freedom Portable Driver during hands-on stations. According to the company, small-group rotations provide direct device interaction and guided scenarios for device management and patient-care best practices.

Did Picard Medical (PMI) hold other SynCardia training events before THT 2026?

Yes, the company recently held a SynCardia Training Village in Houston earlier the same week. According to the company, the THT session follows that event and is part of a broader clinical education and commercial expansion strategy.